Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9378120 | 0.81 | RIPK1 (0.88) | RIPK1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9370134 | 0.80 | RIPK1 (1.00) | RIPK1L3MBTL1POLB | |
| SCHEMBL9378607 | 0.77 | RIPK1 (0.80) | RIPK1KMT2AHSD17B10L3MBTL1 | |
| SCHEMBL9378782 | 0.77 | RIPK1 (0.80) | RIPK1MEN1KMT2AMAPTF2 | |
| SCHEMBL9380034 | 0.76 | RIPK1 (0.70) | RIPK1MEN1KMT2AMAPTCHRNB2 | |
| SCHEMBL9379507 | 0.76 | RIPK1 (0.70) | RIPK1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL9378720 | 0.76 | RIPK1 (0.70) | RIPK1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL29595423 | 0.76 | RIPK1 (0.66) | RIPK1MEN1KMT2AMAPTCHRNB2 | |
| SCHEMBL179757 | 0.76 | RIPK1 (0.66) | RIPK1MEN1KMT2AMAPTCHRNB2 | |
| SCHEMBL179758 | 0.76 | RIPK1 (0.66) | RIPK1MEN1KMT2AMAPTCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0322691-B1 | Process for producing 1-acyl-2-pyrazoline derivatives | MITSUI TOATSU CHEMICALS (JP) | 1994-06-15 | — | — | EP | claimed |
| EP-0295695-B1 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS (JP) | 1994-06-08 | — | — | EP | claimed |
| US-4895947-A | Process for producing 1-acyl-2-pyrazoline derivative | MITSUI TOATSU CHEMICALS, INC. (JP) | 1990-01-23 | — | — | US | claimed |
| EP-0322691-A1 | Process for producing 1-acyl-2-pyrazoline derivatives | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-07-05 | — | — | EP | claimed |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| CN-112370452-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-10899716-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-26 | — | — | US | disclosed |
| CN-107624111-B | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| WO-2016185423-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
| EP-0322691-B1 | Process for producing 1-acyl-2-pyrazoline derivatives | MITSUI TOATSU CHEMICALS (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0295695-B1 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-4990529-A | Nervous system disorder | MITSUI TOATSU CHEMICALS (JP) | 1991-02-05 | — | — | US | disclosed |
| US-4895947-A | Process for producing 1-acyl-2-pyrazoline derivative | MITSUI TOATSU CHEMICALS, INC. (JP) | 1990-01-23 | — | — | US | disclosed |
| EP-0322691-A1 | Process for producing 1-acyl-2-pyrazoline derivatives | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4839376-A | Pyrazoline derivatives for treating cerebrovascular diseases | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0295695-A2 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 414/4885MEN1 1603/4885KMT2A 487/4885 |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885MEN1 1767/4885KMT2A 475/4885 |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885MEN1 1767/4885KMT2A 475/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885MEN1 1767/4885KMT2A 475/4885 |
| US-10899716-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885MEN1 1767/4885KMT2A 475/4885 |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 405/4885MEN1 1767/4885KMT2A 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.